Following the March 20, 2026 patent expiry of semaglutide, India is witnessing a rapid influx of generic GLP-1 receptor agonists. This shift is reshaping market dynamics, with evolving regulatory ...

Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...

Muriel, from the Auxiliary of Social Life, works at the home of Mr. T, who has multiple sclerosis, in Pas de Calais, France, on June 11, 2023. (Astier / BSIP via AFP) (CN) — For people living with ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Abstract: Generic Code Clone Detection (GCCD) is a tool that implemented distance measure as the method to detect code clones in the Java applications. This tool detects irrespective of code clone ...

Highmark recently shared how it increased generic and biosimilar access to members, focusing on drugs for multiple sclerosis, cancer and autoimmune conditions. The insurer has been working with ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...